Jonas Renz - Managing Director & Co-Founder
Jonas joined Secarna Pharmaceuticals in 2015 as its first Managing Director.
After graduating from Oxford University, Jonas joined Goldman Sachs’ Principal Investment Area in London, where he worked on a number of private equity transactions for the Goldman Sachs Capital Partners family of funds.
In 2006, he moved to Och-Ziff Capital Management in London, where his responsibilities included special situations and equity long/short investments. In 2009, he founded an investment management company in Berlin and in 2012, he joined Sterna Biologicals as Managing Director.
Christian Pangratz – Managing Director
Christian came to Secarna in January 2018 as its second Managing Director.
Prior to joining Secarna, Mr. Pangratz worked in executive and leadership positions at Vectura, SkyePharma, Activaero, Nektar Therapeutics, Pfizer and Bayer in Europe, the U.S. and Asia.
The focus of his work was on new product planning, product marketing, product management, marketing communications, public relations, investor relations, alliance management, business and corporate development. Christian also served as Non-Executive Director on the Board of Directors of two companies in Switzerland and a China-based joint venture.
Throughout his career, Mr. Pangratz played an instrumental role in growing companies and completing highly successful corporate and business development transactions valued in excess of US$ 5.1 billion.
Christian earned both a bachelor’s degree in Business Administration and a master’s degree in International Business from Webster University in Vienna/Austria.
Frank Jaschinski – Chief Scientific Officer
Frank joined Secarna in 2015 as its first CSO and is an expert in preclinical drug discovery and development of antisense oligonucleotides.
Dr. Jaschinski`s therapeutic expertise is rooted in the fields of oncology and metabolic diseases. Before joining Secarna, Frank worked in scientific leadership positions at Antisense Pharma / Isarna Therapeutics and The Genetics Company.
He has profound knowledge in conceptualizing, developing and evaluating ASO-based, targeted therapies. In the course of his career, Frank has played a central role in establishing new, high value ASO discovery and development pipelines.
Dr. Jaschinski is an active contributor to the international scientific and biopharmaceutical discovery and development community. As such, he receives invitations to present his and his team`s work at international conferences and published it in major peer-reviewed publications.